

Special Issue

Rheumatoid Arthritis: New Advances in Personalized Therapies

Message from the Guest Editor

Presently, healthcare is moving towards a patient-centered care approach. Therefore, the therapy management of rheumatoid arthritis is changing as well. In recent decades, new drugs have emerged, creating more choices for people. However, until now, there has not been a therapy that works for all patients. Patients may find themselves cycling through medications, hence risking prolonged symptoms and disease progression until a suitable treatment is found. Personalized medicine is centered around developing and tailoring medication decisions to patients based on their unique characteristics or biomarkers. Existing evidence suggests that the implementation of personalized medicine in daily practice for rheumatoid arthritis should be our priority. Therefore, new data will bring advances in the personalized treatment of patients with rheumatoid arthritis.

Guest Editor

Prof. Dr. Serena Guiducci

Department Experimental and Clinical Medicine, Division of Rheumatology, Careggi University Hospital, University of Florence, 50141 Florence, Italy

Deadline for manuscript submissions

30 April 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/222412

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).